Can intestinal mucosal inflammation reduce fat digestion even with normal pancreatic elastase?

In patients presenting with digestive distress, fat malabsorption can occur independently of exocrine pancreatic dysfunction. This phenomenon is highly relevant in clinical evaluations where standard pancreatic markers appear normal.

Pathophysiology of mucosal disruption

• Epithelial barrier damage: Active intestinal mucosal inflammation (such as that seen in celiac disease or inflammatory bowel disease) causes structural damage to the mucosal barrier. This leads to enterocyte injury and villous atrophy, directly impairing critical brush-border enzyme activity and epithelial transporter functions.
• Role of secretory IgA (sIgA): Elevated fecal sIgA serves as a key clinical biomarker of heightened mucosal immune activation and response to luminal antigens. Rather than acting as a direct causal driver of malabsorption, elevated sIgA reflects the ongoing mucosal inflammation that disrupts normal digestive and absorptive processes.

Intestinal-phase fat malabsorption

• Mechanisms of lipid malabsorption: When mucosal integrity is compromised, the downstream efficiency of fat digestion and absorption declines. While luminal triglyceride hydrolysis remains intact, the damaged intestinal epithelium cannot properly transport, pack, or assimilate digested lipids (such as through chylomicron transport pathways).
• Independence from pancreatic function: This reduction in fat digestion efficiency occurs even in the presence of normal exocrine pancreatic function, as indicated by normal fecal pancreatic elastase levels. Under these conditions, pancreatic enzyme secretion is sufficient, but mucosal-phase defects prevent nutrient uptake.

Bottom line

• Normal fecal pancreatic elastase does not rule out fat malabsorption; intestinal mucosal inflammation and elevated secretory IgA indicate an intestinal-phase digestive defect where damaged epithelial tissue fails to absorb fats despite adequate pancreatic enzyme activity.